ImmunoGen (IMGN) Stock Price
ImmunoGen Price
Over the last 19 years ImmunoGen grew revenue by 13.5% annually, reaching 287.61 M USD. For ImmunoGen, the net margin of -25.6% is up versus -148.4% a few years ago.
ImmunoGen stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of ImmunoGen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ImmunoGen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ImmunoGen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | ImmunoGen Price |
|---|
ImmunoGen Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
ImmunoGen Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.09 | 0.06 | 0.12 | 0.05 | 0.08 | 0.13 | 0.11 | 0.11 | 0.29 | 0.55 | 0.54 | 0.76 | 1.22 | 1.32 | 1.30 | 1.41 |
| 44.07 | -29.41 | 91.67 | -53.91 | 54.72 | 60.98 | -18.18 | – | 165.74 | 90.24 | -1.47 | 40.71 | 61.16 | 8.20 | -1.36 | 8.29 |
| -30.59 | -143.33 | -20.87 | -226.42 | -39.02 | 12.88 | 100.00 | 100.00 | 98.61 | 98.61 | 98.61 | 98.61 | 98.61 | 98.61 | 98.61 | 98.61 |
| -0.03 | -0.09 | -0.02 | -0.12 | -0.03 | 0.02 | 0.11 | 0.11 | 0.28 | 0.54 | 0.53 | 0.75 | 1.20 | 1.30 | 1.28 | 1.39 |
| -60.00 | -123.00 | -79.00 | -160.00 | -92.00 | -135.00 | -220.00 | -219.00 | -80.00 | 116.00 | -538.00 | -757.00 | 615.00 | 734.00 | 700.00 | 785.00 |
| -70.59 | -205.00 | -68.70 | -301.89 | -112.20 | -102.27 | -203.70 | -202.78 | -27.87 | 21.25 | -100.00 | -100.00 | 50.41 | 55.61 | 53.76 | 55.67 |
| -60.00 | -143.00 | -96.00 | -167.00 | -122.00 | -66.00 | -222.00 | -222.00 | -73.00 | 91.00 | 88.00 | 216.00 | 481.00 | 540.00 | 499.00 | 538.00 |
| -15.49 | 138.33 | -32.87 | 73.96 | -26.95 | -45.90 | 236.36 | – | -67.12 | -224.66 | -3.30 | 145.45 | 122.69 | 12.27 | -7.59 | 7.82 |
| 86.97 | 87.10 | 124.58 | 147.29 | 148.81 | 191.09 | 215.83 | 254.41 | 287.59 | 287.59 | 287.59 | 287.59 | 287.59 | 287.59 | 287.59 | 287.59 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales ImmunoGen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ImmunoGen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ImmunoGen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares ImmunoGen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ImmunoGen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
ImmunoGen stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
ImmunoGen Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
ImmunoGen business model & stock analysis
ImmunoGen SWOT Analysis
Strengths
[ { "heading": "1.", "text": "Strong" } ]
[ { "heading": "2.", "text": "Extensive" } ]
[ { "heading": "3.", "text": "Collaborations" } ]
Weaknesses
[ { "heading": "1.", "text": "Heavy" } ]
[ { "heading": "2.", "text": "Limited" } ]
[ { "heading": "3.", "text": "Vulnerability" } ]
Opportunities
[ { "heading": "1.", "text": "Increasing" } ]
[ { "heading": "2.", "text": "Growing" } ]
[ { "heading": "3.", "text": "Expansion" } ]
Threats
[ { "heading": "1.", "text": "Intense" } ]
[ { "heading": "2.", "text": "Uncertainty" } ]
[ { "heading": "3.", "text": "Potential" } ]
ImmunoGen Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
ImmunoGen Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
ImmunoGen historical P/E ratio, EBIT multiple, and P/S ratio
ImmunoGen annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
ImmunoGen shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
ImmunoGen Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 12/4/2023 | Downgrade | OverweightNeutral | 51 | |
| 12/4/2023 | Downgrade | OverweightEqual Weight | 33 | |
| 12/1/2023 | Downgrade | BuyHold | 47 | |
| 12/1/2023 | Downgrade | BuyNeutral | 30 | |
| 12/1/2023 | Downgrade | OutperformMarket Perform | – | |
| 12/1/2023 | Downgrade | OverweightEqual Weight | 33 | |
| 11/30/2023 | Downgrade | BuyNeutral | – | |
| 11/3/2023 | Maintained | Buy | – | |
| 9/13/2023 | Upgrade | NeutralOverweight | 80 | |
| 9/12/2023 | Upgrade | NeutralOverweight | 80 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
ImmunoGen Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 4/26/2024 | 0.04USD | - | 125.96 MUSD | - | 2024 Q1 |
| 2/28/2024 | 0.13USD | - | 132.06 MUSD | - | 2023 Q4 |
| 7/27/2023 | -0.26USD | - | 33.94 MUSD | - | 2023 Q2 |
| 5/4/2023 | -0.30USD | - | 21.42 MUSD | - | 2023 Q1 |
| 2/23/2023 | -0.31USD | - | 17.09 MUSD | - | 2022 Q4 |
| 11/4/2022 | -0.26USD | - | 12.66 MUSD | - | 2022 Q3 |
| 7/29/2022 | -0.22USD | - | 16.42 MUSD | - | 2022 Q2 |
| 5/6/2022 | -0.22USD | - | 21.80 MUSD | - | 2022 Q1 |
| 2/25/2022 | -1.74USD | - | 26.03 MUSD | - | 2021 Q4 |
| 10/29/2021 | -0.19USD | - | 19.31 MUSD | - | 2021 Q3 |
EESG©
Eulerpool ESG Scorecard© for the ImmunoGen stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
ImmunoGen shareholder structure
| % | Name |
|---|---|
10.02302% | |
9.36538% | |
7.35279% | |
6.47631% | |
4.35488% | |
3.18441% |
ImmunoGen Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
33.60% | SEC ↗ | |
23.28% | SEC ↗ | |
10.96% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
8.50% | SEC ↗ | |
8.50% | SEC ↗ | |
6.99% | SEC ↗ |
ImmunoGen Executives and Management Board
9 members · avg. age 54 · 78 % women
Mr. Michael Vasconcelles (59)
Executive Vice President - Research, Development, and Medical Affairs
3.81 M USD
Dr. Anna Berkenblit (53)
Senior Vice President, Chief Medical Officer
Ms. Stacy Coen (52)
Senior Vice President, Chief Business Officer
Dr. Theresa Wingrove (65)
Senior Vice President - Regulatory Affairs and Quality
Ms. Renee Lentini (45)
Principal Accounting Officer
Ms. Lauren White (44)
Chief Financial Officer, Senior Vice President
Ms. Heather Huet
Senior Vice President, Chief Scientific Officer
ImmunoGen Supply Chain
ImmunoGen Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.66 | 0.41 | 0.43 | ||
| 2 | 0.73 | 0.59 | 0.41 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.70 | -0.56 | -0.51 | ||
| 2 | -0.73 | -0.63 | -0.38 | ||
| 3 | 0.29 | 0 | -0.33 | ||
| 4 | -0.58 | -0.29 | -0.10 | ||
| 5 | -0.70 | -0.38 | -0.06 |
Frequently asked questions about ImmunoGen
The business model of ImmunoGen Inc is focused on the development of targeted antibody-drug conjugates (ADCs) for the treatment of cancer. ADCs leverage the specificity of antibodies to selectively deliver potent cytotoxic drugs to cancer cells, aiming to minimize side effects. ImmunoGen's proprietary technology, known as ADC technology, involves the use of monoclonal antibodies that target specific proteins overexpressed on cancer cells. These antibodies are conjugated with cytotoxic agents to create ADCs, which bind to cancer cells, allowing for targeted delivery of the drug payload. By advancing its technology and collaborations, ImmunoGen aims to provide innovative treatment options for patients with cancer.
ImmunoGen Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of ImmunoGen Inc in the market include pharmaceutical companies such as Roche Holding AG, Pfizer Inc, and Bristol-Myers Squibb Company.
ImmunoGen Inc is a pharmaceutical company founded in 1981 and headquartered in Waltham, Massachusetts. With a focus on developing targeted antibody-drug conjugates (ADCs), ImmunoGen has been a pioneer in the field of cancer therapeutics. The company's innovative technology aims to deliver treatment directly to cancer cells while minimizing damage to healthy cells. ImmunoGen has partnered with various pharmaceutical companies to accelerate the development and commercialization of ADCs. Over the years, ImmunoGen has gained recognition for its expertise in ADC research and continues to advance its pipeline of novel therapies, making significant contributions to the field of oncology.
ImmunoGen Inc has achieved several significant milestones. The company successfully developed and obtained FDA approval for its targeted anti-cancer therapy, Kadcyla. This milestone revolutionized the treatment of HER2-positive breast cancer, providing a more effective and less toxic treatment option. ImmunoGen Inc also partnered with leading pharmaceutical companies like Roche, Amgen, and Takeda, further validating their novel technology platform. Additionally, the company has made notable progress in advancing their pipeline candidates, including IMGN632 and IMGN151, targeting various hematological malignancies. These achievements demonstrate ImmunoGen Inc's commitment to groundbreaking research and the potential to significantly impact cancer treatment.
ImmunoGen Inc, a leading biotechnology company, primarily operates in the United States. With its headquarters located in Waltham, Massachusetts, ImmunoGen Inc primarily focuses on the development and commercialization of innovative antibody-drug conjugate (ADC) therapies for the treatment of various types of cancer. By leveraging its proprietary technology platform, ImmunoGen Inc has gained recognition and presence in the US healthcare industry. As a US-based company, ImmunoGen Inc has been actively involved in collaborations and partnerships with other biopharmaceutical companies to expand its global reach and potentially introduce its revolutionary ADC therapies to patients worldwide.
ImmunoGen Inc represents values of innovation, dedication, and patient-centricity. With a strong corporate philosophy focused on developing targeted cancer therapies, ImmunoGen is committed to improving the lives of patients battling cancer. By harnessing the power of its unique Antibody-Drug Conjugate (ADC) technology, ImmunoGen strives to deliver transformative treatments that specifically target cancer cells while sparing healthy cells. The company's dedication to research, collaboration, and delivering breakthrough therapies sets it apart in the biotechnology industry. ImmunoGen Inc prioritizes patient well-being and relentlessly pursues advancements in precision medicine to shape the future of cancer treatment.
19 analysts currently rate the ImmunoGen stock: 7 recommend buying, 12 holding and 0 selling. For 2026, analysts expect ImmunoGen to generate revenue of 757.20 M USD and earnings per share of 0.75 USD.
The ImmunoGen share (IMGN) is listed on 8 stock exchanges, including: NASDAQ (IMGN), XETRA (IMU.DE), Frankfurt (IMU.F), München (IMU.MU), Düsseldorf (IMU.DU), London (0A8K.L), London (0A8K.L), SIX (Zürich) (IMU.SW).
ImmunoGen Inc is a biotechnology company specializing in the development of innovative therapy approaches for the treatment of cancer. The company's business model is based on the discovery and development of drugs that selectively destroy cancer cells while sparing the surrounding healthy tissue. ImmunoGen utilizes its own technology platform called Antibody-Drug Conjugates (ADCs) for this purpose. ADCs are a new class of drugs that can target cancer cells specifically. They consist of three components: an antibody that binds specifically to cancer cells, a drug that kills the cancer cells, and a linker that connects the two components. By combining these components, ADCs enable targeted tumor destruction and reduce the burden on healthy tissue. ImmunoGen's flagship product is the ADC candidate Mirvetuximab Soravtansine, which is currently being tested in Phase 3 clinical trials for the treatment of ovarian cancer. Mirvetuximab Soravtansine has higher efficacy and fewer side effects compared to conventional chemotherapeutics. In addition, ImmunoGen is developing other ADC candidates in various stages of clinical development. In addition to ADC development, ImmunoGen also operates a service business focused on the manufacturing and optimization of ADCs for other pharmaceutical companies. ImmunoGen has extensive experience in ADC manufacturing and offers this expertise as a service. Furthermore, ImmunoGen collaborates with other companies and research institutions to further develop and expand the ADC technology platform. Another business area of ImmunoGen is the research and development of new technology platforms. The company continuously invests in the exploration of new approaches for cancer therapy. This includes the ABC technology platform, which aims to improve the short-term stability of ADCs while increasing their efficacy. ImmunoGen aims to become a leading biotechnology company in the field of cancer therapy. With its innovative ADC technology platform and the development of promising candidates like Mirvetuximab Soravtansine, ImmunoGen is on track to achieve this goal. With a broad portfolio of products and services, ImmunoGen is well-equipped to withstand an increasingly complex and volatile industry.
The expected revenue of ImmunoGen is 757.20 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of ImmunoGen is 216.89 M USD. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for ImmunoGen at the moment.
The P/S cannot be calculated for ImmunoGen currently.
The Eulerpool Quality Score for ImmunoGen is 4/10.
The ISIN of ImmunoGen is US45253H1014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ImmunoGen is 878613. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ImmunoGen is IMGN. The ticker symbol is used to trade ImmunoGen shares on the stock exchange.
ImmunoGen is assigned to the 'Health' sector.
The dividends of ImmunoGen are distributed in USD.
ImmunoGen stock
ImmunoGen Peer Group
ImmunoGen Ticker
ImmunoGen FIGI
All fundamentals and in-depth analysis of ImmunoGen
Our stock analysis for ImmunoGen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmunoGen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.